slotscasinorealmoney| Yuandong Biotech: The Phase III clinical trial of jumagliptin tablets as a single agent for the treatment of type 2 diabetes has achieved the expected goals

News summary

Yuandong Bio: The Phase III clinical trial of Uoglitine tablets as a single agent for the treatment of type 2 diabetes has achieved the expected goal. Securities Times e Company Newsslotscasinorealmoney, Yuandong Biotech (688513) announced on the evening of April 30 that the phase III clinical trial of the company's independently developed new class 1 drug, Junagliptin tablets, for the single-agent treatment of type 2 diabetes, has been completedslotscasinorealmoney...

Newsletter text

Yuandong Biotech: The Phase III clinical trial of Junagliptin tablets as a single agent for the treatment of type 2 diabetes has achieved the expected goals Securities Times Company e News. Yuandong Biotech (688513) announced on the evening of April 30 that the company's independently developed new class 1 drug Junagliptin tablets as a single agent for the treatment of type 2 diabetes has recently obtained a clinical trial summary report and achieved the expected goals. The results of the phase III clinical trial showed that Junagliptin tablets alone could significantly improve glycosylated hemoglobin (HbA1c), fasting blood glucose and 2h postprandial blood glucose in patients with type 2 diabetes who were not well controlled by diet and exercise alone.